MiMedx Group (MDXG) AI Stock Analysis

• Market Cap: $1.03B
• Dividend Yield: N/A
• Average Volume (3M): 525.38K
• Price to Earnings (P/E): 32.3
• Beta (1Y): 0.76
• Revenue Growth: 6.85%
• EPS Growth: -67.67%
• Country: US
• Employees: 837
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 147,959,410
• 10 Day Avg. Volume: 420,210
• 30 Day Avg. Volume: 525,378
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 2.30
• Enterprise Value/Gross Profit: 2.81
• Enterprise Value/Ebitda: 14.78
• 1Y Price Target: $12.00
• Price Target Upside: 72.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 75 Outperform
• Price Target: $8.00 ▲(14.78% Upside)

MiMedx Group's strong financial performance and positive earnings call are the primary drivers of its stock score. While the company shows robust revenue growth and profitability, technical indicators suggest mixed market sentiment, and the valuation appears high. The potential impact of Medicare reimbursement changes and clinical trial delays are notable risks.

Positive Factors

Revenue Growth

The company's record revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Cash Flow Generation

Robust cash flow generation enhances financial stability, providing flexibility for strategic investments and operational resilience.

Product Development

Innovative product development and strategic partnerships enhance competitive positioning and long-term growth potential.

Negative Factors

Medicare Reimbursement Changes

Changes in Medicare reimbursement may alter market dynamics, potentially affecting pricing and market share, posing a risk to future revenues.

Clinical Trial Delays

Delays in clinical trials can hinder product approvals and market entry, impacting competitive advantage and revenue growth.

Operational Cost Challenges

Rising operational costs may pressure margins, affecting profitability and requiring strategic cost management to sustain growth.

MiMedx Group Business Overview & Revenue Model

Company Description

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

How the Company Makes Money

MiMedx generates revenue primarily through the sale of its regenerative medicine products, which are marketed to hospitals, outpatient surgical centers, and clinics. Key revenue streams consist of direct sales of allograft tissue products used in wound care and surgical procedures. The company benefits from strategic partnerships with healthcare providers and distributors that help expand its market reach. Additionally, MiMedx may receive reimbursements from insurance companies for its products, further contributing to its earnings. The company's focus on innovation and clinical evidence supporting the efficacy of its products also plays a significant role in driving sales and attracting new customers.

MiMedx Group Financial Statement Overview

Summary

MiMedx Group has shown strong revenue growth and profitability improvements, with a robust gross profit margin of 81.9% and a positive net profit margin of 11.4% for TTM 2025. The solid balance sheet with low leverage and strong cash flow generation underscores financial stability.

Income Statement

MiMedx Group has shown strong growth in revenue over the observed periods, with a notable increase from $267.8M in 2022 to $352.4M in TTM (Trailing-Twelve-Months) 2025. Gross profit margin is robust at 81.9% for TTM, indicating efficient cost management. The net profit margin has turned positive, reaching 11.4% in TTM 2025 from negative figures in previous years, signaling improved profitability. However, the decline in EBIT from 2024 to TTM 2025 suggests some operational cost challenges.

Balance Sheet

The company's balance sheet reflects a solid equity position with an equity ratio of 74.98% in TTM 2025, indicating a strong capital structure. The debt-to-equity ratio is very low at 0.01, showcasing minimal leverage, which reduces financial risk. Return on equity is positive at 19.81%, reflecting efficient use of equity to generate profits. Nonetheless, the high level of cash reserves relative to debt suggests missed opportunities for investment or growth.

Cash Flow

MiMedx Group demonstrates strong cash flow generation with free cash flow growing significantly, highlighted by a free cash flow of $68.7M in TTM 2025. The operating cash flow to net income ratio is favorable, indicating efficient cash generation from operations. Furthermore, the free cash flow to net income ratio of 1.71 signifies robust cash conversion efficiency. Overall, the cash flow position is solid, underpinning financial stability and flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	352.38M	348.88M	321.48M	267.84M	258.62M	248.23M
Gross Profit	288.54M	288.81M	266.84M	219.53M	215.33M	208.90M
EBITDA	54.95M	64.34M	40.52M	-10.69M	-1.89M	-45.76M
Net Income	40.18M	42.42M	67.44M	-30.20M	-10.29M	-49.28M
Balance Sheet
Total Assets	270.42M	263.92M	239.05M	171.43M	187.93M	202.03M
Cash, Cash Equivalents and Short-Term Investments	106.43M	104.42M	82.00M	65.95M	87.08M	95.81M
Total Debt	18.66M	24.84M	48.10M	48.59M	48.13M	47.70M
Total Liabilities	67.64M	70.81M	96.33M	189.42M	187.85M	202.18M
Stockholders Equity	202.78M	193.11M	142.72M	-17.99M	82.00K	-150.00K
Cash Flow
Free Cash Flow	68.32M	64.52M	24.79M	-20.58M	-5.45M	-34.82M
Operating Cash Flow	67.55M	66.20M	26.77M	-17.89M	-1.98M	-30.26M
Investing Cash Flow	-3.96M	-9.58M	-2.15M	-2.66M	-3.40M	-4.55M
Financing Cash Flow	-3.61M	-34.20M	-8.57M	-580.00K	-3.35M	61.56M

MiMedx Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.97
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Negative. The current price of 6.97 is below the 20-day moving average (MA) of 7.11, below the 50-day MA of 6.99, and below the 200-day MA of 7.57, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.20 is Neutral, neither overbought nor oversold. The STOCH value of 34.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDXG.

MiMedx Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	75 Outperform	$1.03B	32.31	16.62%	―	6.85%	-67.67%
ARDX	59 Neutral	1.57B	-27.63	-40.41%	―	83.88%	15.24%
OCUL	56 Neutral	2.18B	-9.82	-70.85%	―	-7.26%	-15.33%
LQDA	52 Neutral	2.30B	-15.89	-168.74%	―	30.20%	-7.22%
CLDX	50 Neutral	1.63B	-8.14	-30.46%	―	-30.25%	-9.70%
IOVA	46 Neutral	821.41M	-1.85	-55.82%	―	636.99%	27.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

MiMedx Group Corporate Events

MiMedx Group Joins Cantor Global Healthcare Conference

MiMedx Group announced its participation in the Cantor Global Healthcare Conference on September 3, 2025, and updated its investor presentation. The company is poised to expand its market presence with a focus on growth outside the U.S., increased funding for research, and an expanded product portfolio. The announcement highlights MiMedx’s strategic priorities, including product diversification and enhancing customer intimacy, which are expected to drive growth and profitability. The company also emphasizes its commitment to advocating for Medicare spending reform and leveraging favorable market trends to boost its financial performance.

The most recent analyst rating on (MDXG) stock is a Buy with a $8.50 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.